Take a look at the latest blog post from Dale Yuzuki, published on the Silent Valley Consulting website, about a technology from 2008 to 2011 that was the world’s first “true single molecule sequencer”. You can access the post here.
Do you listen to podcasts? Would you be interested in learning about how Olink Proteomics’ technology is applied in biomarker discovery, drug discovery, proteogenomics, and routine research into biological mechanisms? If so, here’s the first ‘teaser’ advertisement, and we will be launching the first episode in a week. You can listen to the episode by … Read more
In a large meta-analysis, circulating protein levels of severe COVID patients along with many thousands of genomic datasets leads to an exciting discovery: a mutation in a gene called FAS that turns it into a non-membrane-bound, soluble form, interrupting normal immune function. In addition, an on-market chemotherapeutic drug has been shown to lower soluble FAS, … Read more
With Singular Genomics announcing the new G4 system at the end of 2021, and Element Biosciences announcing the AVITI system in March 2022, here is a look at the existing state-of-the-art systems in a single graphic After spending some time in Los Angeles this week visiting a few existing and potential customers for Olink Proteomics, … Read more
A new approach to next-generation sequencing, a little-known company unwraps an instrument that competes directly with the Illumina NextSeq 2000 with a third more of the throughput at half the consumables price For a technology that started in 2005 with the first 454 / Roche FLX next-generation sequencing (NGS) platform, followed in 2007 with the … Read more
A new post that presents the concepts underlying combining 30 years of genomic research with the proteins in circulation to determine not only disease risk but the cause of disease.
With a robust collection of 500,000 individuals, the UK Biobank will succeed in its mission to study the determinants of disease through genetics and proteomics combined with extensive electronic health records and ongoing assessments What the UK Biobank is and its current status The UK Biobank (abbreviated UKB or UKBB) began in 2006 as a … Read more
Promising technology out of UCSF to use droplets as containers for single-cell interaction assays Way back in 2009 I remember the first time my sales manager at RainDance Technologies presented their core technology to a sophisticated group at the US National Institutes of Health, with an introduction to microfluidics. He began by saying “Microfluidics has … Read more
An economical and scalable benchtop instrument bringing multiplex protein assays to individual laboratories or centralized core facilities The Olink original offering: 96-plex on the Fluidigm Biomark Olink started its commercial laboratory in the Boston area in 2016, based upon the Proximity Extension Assay technology and method published in a 2014 PLoS One paper entitled “Homogenous … Read more
A direct-to-consumer COVID-19 test available via Amazon with a convenient saliva sample-type and fast central-laboratory processing The current environment for this third (or is it fourth) wave of COVID-19 SARS-CoV-2 infections is reaching new records. The first week of January 2021 is seeing a 7-day moving average of cases above 234,000 per day (the prior … Read more
Abbott’s new $5, 15-minute, 50 million per month test is a game-changer This past week an eventful announcement came from Abbott Laboratories, manufacturer of several diagnostic platforms, including several already approved fro COVID-19 testing including amplification-based IDNow, and a few antibody automated systems, one prominent one being the Architect. Now on their Binax platform, which … Read more
It was about a year ago that I highlighted here some neat graphene technology out of Cardea Biosciences, and in that context I mentioned CRISPR-based diagnostics. (If interested, you can find the post here.) The FDA recently approved under Emergency Use Authorization (EUA) Sherlock BioSciences’ SARS-CoV-2 Rapid diagnostic (FDA EUA page is here) and let’s … Read more